Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

High-Dose Therapy Followed by Autologous Stem Cell Transplant for Multiple Myeloma

By: Andrew Goldstein
Posted: Monday, March 12, 2018

High-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) for patients with multiple myeloma was associated with superior progression-free survival than standard-dose therapy but no significant difference in overall survival, according to a meta-analysis of phase III trials published in JAMA Oncology. Thus, for Binod Dhakal, MD, MS, of the Medical College of Wisconsin, and colleagues, ASCT remains the preferred therapy for transplant-eligible patients with myeloma.

For the review, 4 randomized clinical trials involving a total of 2,421 patients were included in the conventional meta-analysis; they compared HDT/ASCT with standard-dose therapy using novel agents. In addition, 5 randomized clinical trials (3,171 patients) comparing single HDT-ASCT with bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and tandem transplantation were selected for network meta-analysis.

When compared with standard-dose therapy, HDT/ASCT yielded a combined odds for complete response of 1.27. The progression-free survival also seemed to favor HDT, with a combined hazard ratio of 0.55; however, a significant difference in overall survival was not shown, with similar overall survival across the four approaches. Dr. Dhakal and colleagues also found that tandem HDT/ASCT and single HDT/ASCT plus VRD were associated with better progression-free survival than single HDT/ASCT alone.

“Longer follow-up may better delineate any overall survival benefit; however, it is likely to be affected by effective postrelapse therapy,” the investigators noted.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.